Risk Management of Medicines and Compensation for Harm I. Ralph Edwards Editorial 19 October 2012 Pages: 87 - 90
A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge Jeffrey K. AronsonDeirdre PriceRobin E. Ferner Special Article 19 October 2012 Pages: 91 - 98
Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions Manfred HaubenJeffrey K. Aronson Leading Article 19 October 2012 Pages: 99 - 110
Treating Hypertension in Older Adults Wilbert S. Aronow Practical Drug Safety 19 October 2012 Pages: 111 - 118
A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation Kate CahillLindsay SteadTim Lancaster Review Article 19 October 2012 Pages: 119 - 135
Drug-versus-Drug Adverse Event Rate Comparisons Alan M. HochbergRonald K. PearsonStephanie J. Reisinger Short Communication 19 October 2012 Pages: 137 - 146
Hepatotoxicity Associated with Long-versus Short-Course HIV-Prophylactic Nevirapine Use June M. McKoyCharles L. BennettJorge P. Parada Original Research Article 19 October 2012 Pages: 147 - 158
Effect of Macrolide and Fluoroquinolone Antibacterials on the Risk of Ventricular Arrhythmia and Cardiac Arrest Antonella ZambonHernan PoloGiovanni Corrao Original Research Article 19 October 2012 Pages: 159 - 167
Examining the Tolerability of the Non-Sedating Antihistamine Desloratadine Deborah LaytonLynda WiltonSaad A.W Original Research Article 19 October 2012 Pages: 169 - 179